• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Eye Research >Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
【24h】

Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.

机译：与每日两次奥洛他定0.1％眼药水相比，每日一次奥洛他定0.2％眼药水治疗结膜变应原激发引起的眼瘙痒的疗效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Olopatadine 0.1% (Patanol) and olopatadine 0.2% (Pataday) ophthalmic solutions are topical ocular anti-allergic agents with antihistaminic and mast cell stabilizing properties. The efficacy of two doses of olopatadine 0.1% was compared to one dose of olopatadine 0.2% in the prevention of ocular itching associated with allergic conjunctivitis over 24 hours. This double-masked conjunctival allergen challenge (CAC) study found no significant difference in the mean itching scores between two drops of olopatadine 0.1% and one drop of olopatadine 0.2%. Both showed significant activity at the 24-hour time point and were statistically superior to placebo. No adverse events occurred while on drug therapy.
机译：0.1％的奥洛他定（Patanol）和0.2％的奥洛他定（Pataday）眼用溶液是具有抗组胺和肥大细胞稳定特性的局部眼用抗过敏药。将两剂奥洛他定0.1％与一剂奥洛他定0.2％在24小时内预防与过敏性结膜炎相关的眼瘙痒的功效。这项双重掩膜性结膜变应原攻击（CAC）研究发现，两滴0.1％的奥洛他定和0.2％的奥洛他汀的平均瘙痒评分无明显差异。两者均在24小时时间点显示出明显的活性，并且在统计学上优于安慰剂。药物治疗期间未发生不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号